Terns Pharmaceuticals, Inc. Revenue per Share

Revenue per Share of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Revenue per Share growth rates and interactive chart. Calculated as total revenue divided by the number of weighted average shares outstanding in the period. It can be easily compared to the stock price to determine how revenue is an investor getting for every $1 paid for a stock.


Highlights and Quick Summary

  • Revenue per Share for the quarter ending March 31, 2022 was 0.0 (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly Revenue per Share decreased by NaN%
  • Annual Revenue per Share for 2021 was 0.04 (a Infinity% increase from previous year)
  • Annual Revenue per Share for 2020 was 0.0 (a NaN% decrease from previous year)
  • Annual Revenue per Share for 2019 was 0.0 (a NaN% decrease from previous year)
  • Twelve month Revenue per Share ending March 31, 2022 was 0.0 (a NaN% decrease compared to previous quarter)
  • Twelve month trailing Revenue per Share decreased by NaN% year-over-year
Trailing Revenue per Share for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
0.0 0.0 0.0 0.0
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Revenue per Share of Terns Pharmaceuticals, Inc.

Most recent Revenue per Shareof TERN including historical data for past 10 years.

Interactive Chart of Revenue per Share of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Revenue per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.0
2021 0.04 0.0 0.0 0.0 0.04
2020 0.0 0.0 0.0 0.0 0.0
2019 0.0 0.0
2018 0.0

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.